Aldeyra Therapeutics (ALDX) Updates on Late-Stage Clinical Trials; Plans to Advance ADX-102 to Phase 2b
- Nasdaq, S&P tumble as Netflix, chip stocks drag; AmEx boosts Dow
- Sony/Apollo bid for Paramount could be worth as much as $29 billion - Source
- Netflix Q1 earnings top estimates on blowout subscriber growth
- Nasdaq tumbles, Treasuries dip amid earnings, geopolitical crosscurrents
- Gold prices rally past $2,400 on reports of Israel strikes on Iran
- Tritium DCFC Limited (DCFC): Three Australian subsidiaries were determined to be insolvent or likely to become insolvent
- Hasbro (HAS) Announces Resignation of Cynthia Williams, President of Wizards of the Coast and Hasbro Gaming
- Jabil falls after placing CEO on paid leave amid internal investigation
- Frontier Communications (FYBR) says third party had gained unauthorized access to portions of its information technology environment
- Ibotta (IBTA) Prices 6.56M Share IPO at $88/sh
- Midday movers: Netflix, Super Micro fall; Paramount Global gains
- After-hours movers: Netflix, Intuitive Surgical, Nordstrom, KB Home
- Midday movers: Tesla, Blackstone, Las Vegas Sands fall; DR Horton rises
- After-hours movers: Alcoa rises; Equifax and Las Vegas Sands fall
- Midday movers: Travelers, JB Hunt fall; United Airlines rises
Aldeyra Therapeutics Provides Update on Late-Stage Clinical Trials at 2016 Research and Development Day
September 26, 2016 8:30 AM EDTLEXINGTON, MA -- (Marketwired) -- 09/26/16 -- Aldeyra Therapeutics, Inc. (NASDAQ: ALDX)
First-Ever Vehicle-Controlled Phase III Clinical Trial in Noninfectious Anterior Uveitis
First-Ever Phase III Clinical Trial in Sjgren-Larsson Syndrome
Allergic Conjunctivitis Phase IIb Clinical Trial
Phase IIa Clinical Trial in Dry Eye Syndrome
Aldeyra Therapeutics, Inc. (NASDAQ: ALDX) (Aldeyra), a biotechnology company focused on the development of products to treat diseases related to aldehydes, today provided updates on its plans for late-stage clinical trials at the Aldeyra 2016 Research and Development Day. Aldeyra announced... More